Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.

You may also be interested in...



FDA Commissioner Nomination Hearing Scheduled By Senate Health Committee

Nomination of FDA Acting Commissioner von Eschenbach to the post will be reviewed Aug. 1, although a vote is not anticipated.

FDA Commissioner Nomination Hearing Scheduled By Senate Health Committee

Nomination of FDA Acting Commissioner von Eschenbach to the post will be reviewed Aug. 1, although a vote is not anticipated.

“New” Plan B Emails Say FDA’s “Novel” Concerns Were Not Novel – Waxman

FDA had begun considering the legality of marketing the emergency contraceptive over-the-counter for women age 16 and older and Rx for those under 16 as early as 2004, documents suggest.

Related Content

Topics

UsernamePublicRestriction

Register

PS062788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel